ProBio's Innovative Antibody Platform Set to Transform T Cell Engagers at AACR 2025 ProBio is slated to unveil its groundbreaking CD3 agonistic single-domain antibody platform at AACR 2025, demonstrating its potential in revolutionizing multi-specific antibodies for cancer immunotherapy.

ProBio's Innovative Antibody Platform Set to Transform T Cell Engagers at AACR 2025 #United_States #Chicago #Cancer_Immunotherapy #ProBio #CD3_Antibody